Equity Profile

CORT

Corcept Therapeutics Incorporated

Health CarePharmaceuticals$7.5B

Apr30Thu

Post-Earnings Recap

ReportedQ1-2026After Close4:05 PM EDT

Corcept Therapeutics Misses on EPS, Stock Down 0.15%

Metric	Actual	Expected	Surprise
EPS	$-0.30	$-0.14	-1.01%
Revenue	N/A	$187M	N/A

management commentary, guidance changes, and full analysis available with Pro.

Corcept Therapeutics Misses on EPS, Stock Down 0.15%

Key Numbers

Metric	Actual	Expected	Surprise
EPS	$-0.30	$-0.14	-1.01%
Revenue	N/A	$187M	N/A

Management Commentary

Tone: Unknown

No transcript is on record for this earnings call, so the analysis is based solely on numerical results.

What It Means

Corcept Therapeutics reported a larger-than-expected loss per share, which contributed to a slight decline in its stock price. The company did not provide revenue figures, leaving investors without a complete picture of its financial performance. The stock's minor drop of 0.15% reflects market disappointment over the EPS miss.

Company Snapshot

Corcept Therapeutics Incorporated (CORT) is a pharmaceutical company focused on developing and commercializing drugs that treat serious disorders related to the body's stress hormone, cortisol. With a market cap of $5 billion, the company plays a significant role in the health care sector, particularly in addressing conditions like Cushing's syndrome and other related disorders.

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will help investors gauge the company's financial health this quarter.

$-0.14

Revenue

Revenue figures provide insight into the company's sales performance and market demand for its products.

$187M

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

+4.94%

Avg Stock Reaction

-0.00%

Last Quarter Recap

In Q4-2025, Corcept reported an EPS of $0.20, which was below the expected $0.27, leading to a stock increase of 3.23% the following day. The company has shown mixed performance in previous quarters, with some surprises in earnings.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts are anticipating a challenging quarter for Corcept, with a consensus EPS estimate of $-0.14 and revenue expectations of $187 million. Investors are closely watching how the company navigates its market challenges.

Bull Case

If Corcept can exceed revenue expectations and show signs of profitability, it could boost investor confidence and lead to a positive stock reaction.

Bear Case

Conversely, if the company fails to meet earnings expectations or provides weak guidance, it could lead to a significant decline in stock price.

Key Metrics to Watch

EPS

$-0.14

Earnings per share is a key indicator of profitability and will help investors gauge the company's financial health this quarter.

Revenue

$187M

Revenue figures provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Corcept's revenue meet or exceed the consensus estimate of $187 million?

Revenue performance is critical for assessing the company's market position and growth potential, especially in a competitive pharmaceutical landscape.

What guidance will management provide regarding future earnings and product development?

Forward-looking statements can significantly influence investor sentiment and stock performance, especially if they indicate a shift in strategy or market conditions.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate Corcept's ability to leverage its existing product portfolio for revenue growth, particularly in niche markets.

Supporting Evidence

The options market is pricing in an 8.27% move, indicating expectations of volatility that may not align with the company's historical performance.

Corcept has a history of surprising analysts, with a 63% EPS beat rate in recent quarters, suggesting potential for positive surprises.

Key Risk

If revenue comes in significantly above $187 million, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical as it will indicate how well Corcept is managing its product pipeline and market challenges.

Bull Confirmed If

Exceeding the revenue estimate of $187 million while showing signs of improved profitability.

Bear Confirmed If

Falling short of the revenue estimate and providing weak guidance for future quarters.

Pre-Earnings Positioning

Options Market

Implied Move

±8.27%

Historical Avg

±2.7%

Pricing rich

The options market is pricing in a relatively large move, suggesting that investors expect significant volatility around the earnings announcement.

Options are pricing ±8.3% while CORT has averaged ±2.7% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

63.1%

Calls (13K)P/C Ratio: 0.25Puts (5K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Corcept beats expectations, history suggests the stock could see a modest increase, confirming a positive outlook for the company.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further clarity from management.

Miss

Should the company miss estimates, history suggests a potential decline in stock price as investors react to disappointing performance.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on product pipeline developments and their expected impact on revenue.
2Management's commentary on market conditions and competitive landscape.
3Insights into customer demand for existing products and any new launches.
4Guidance on future earnings and strategic initiatives.
5Responses to analyst questions regarding cost management and profitability.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Apr27

CINFReported

Cincinnati Financial Corporation

RecapView

Apr27

CCKReported

Company Snapshot

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will help investors gauge the company's financial health this quarter.

$-0.14

Revenue

Revenue figures provide insight into the company's sales performance and market demand for its products.

$187M

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

+4.94%

Avg Stock Reaction

-0.00%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Corcept can exceed revenue expectations and show signs of profitability, it could boost investor confidence and lead to a positive stock reaction.

Bear Case

Conversely, if the company fails to meet earnings expectations or provides weak guidance, it could lead to a significant decline in stock price.

Key Metrics to Watch

EPS

$-0.14

Earnings per share is a key indicator of profitability and will help investors gauge the company's financial health this quarter.

Revenue

$187M

Revenue figures provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Corcept's revenue meet or exceed the consensus estimate of $187 million?

Revenue performance is critical for assessing the company's market position and growth potential, especially in a competitive pharmaceutical landscape.

What guidance will management provide regarding future earnings and product development?

Forward-looking statements can significantly influence investor sentiment and stock performance, especially if they indicate a shift in strategy or market conditions.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate Corcept's ability to leverage its existing product portfolio for revenue growth, particularly in niche markets.

Supporting Evidence

The options market is pricing in an 8.27% move, indicating expectations of volatility that may not align with the company's historical performance.

Corcept has a history of surprising analysts, with a 63% EPS beat rate in recent quarters, suggesting potential for positive surprises.

Key Risk

If revenue comes in significantly above $187 million, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical as it will indicate how well Corcept is managing its product pipeline and market challenges.

Bull Confirmed If

Exceeding the revenue estimate of $187 million while showing signs of improved profitability.

Bear Confirmed If

Falling short of the revenue estimate and providing weak guidance for future quarters.

Pre-Earnings Positioning

Options Market

Implied Move

±8.27%

Historical Avg

±2.7%

Pricing rich

The options market is pricing in a relatively large move, suggesting that investors expect significant volatility around the earnings announcement.

Options are pricing ±8.3% while CORT has averaged ±2.7% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

63.1%

Calls (13K)P/C Ratio: 0.25Puts (5K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Corcept beats expectations, history suggests the stock could see a modest increase, confirming a positive outlook for the company.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further clarity from management.

Miss

Should the company miss estimates, history suggests a potential decline in stock price as investors react to disappointing performance.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on product pipeline developments and their expected impact on revenue.
2Management's commentary on market conditions and competitive landscape.
3Insights into customer demand for existing products and any new launches.
4Guidance on future earnings and strategic initiatives.
5Responses to analyst questions regarding cost management and profitability.